Disruptive Behavior Disorder is an indication for drug development with over 60 pipeline drugs currently active. According to GlobalData, preregistered drugs for Disruptive Behavior Disorder have a 87.5% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Disruptive Behavior Disorder compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Disruptive Behavior Disorder overview
Disruptive Behavior Disorders (DBD) encompass conditions like oppositional defiant disorder (ODD) and conduct disorder (CD). These disorders involve persistent patterns of defiant, aggressive, or socially disruptive behaviors in children and adolescents. ODD includes defiant, argumentative behavior, while CD involves more severe behaviors like rule-breaking, aggression, or deceitfulness. Diagnosis considers behavioral assessments, observation, and family history. Treatment involves therapy, behavioral interventions, and sometimes medication. Early identification and intervention are crucial, aiming to teach coping skills, improve social interactions, and address underlying issues to reduce the impact of disruptive behaviors on the individual’s life and their relationships.
For a complete picture of PTSR and LoA scores for drugs in Disruptive Behavior Disorder, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
